Review



ct26 mouse colorectal carcinoma  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC ct26 mouse colorectal carcinoma
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Ct26 Mouse Colorectal Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 3499 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26 mouse colorectal carcinoma/product/ATCC
    Average 99 stars, based on 3499 article reviews
    ct26 mouse colorectal carcinoma - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "Fluorescence tracking Treg movement identifies anti-CCR8 and radiation as a therapeutic combination"

    Article Title: Fluorescence tracking Treg movement identifies anti-CCR8 and radiation as a therapeutic combination

    Journal: iScience

    doi: 10.1016/j.isci.2025.114572

    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with CT26 on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Figure Legend Snippet: Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with CT26 on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

    Techniques Used: Irradiation, Injection



    Similar Products

    ct26 mouse colorectal carcinoma  (ATCC)
    99
    ATCC ct26 mouse colorectal carcinoma
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Ct26 Mouse Colorectal Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26 mouse colorectal carcinoma/product/ATCC
    Average 99 stars, based on 1 article reviews
    ct26 mouse colorectal carcinoma - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    ct26 mouse colorectal carcinoma cells  (ATCC)
    99
    ATCC ct26 mouse colorectal carcinoma cells
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Ct26 Mouse Colorectal Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26 mouse colorectal carcinoma cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    ct26 mouse colorectal carcinoma cells - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    mouse colorectal carcinoma cell line ct26  (ATCC)
    99
    ATCC mouse colorectal carcinoma cell line ct26
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Mouse Colorectal Carcinoma Cell Line Ct26, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse colorectal carcinoma cell line ct26/product/ATCC
    Average 99 stars, based on 1 article reviews
    mouse colorectal carcinoma cell line ct26 - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    ct26 colorectal carcinoma mouse model  (China Pharmaceuticals Inc)
    90
    China Pharmaceuticals Inc ct26 colorectal carcinoma mouse model
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Ct26 Colorectal Carcinoma Mouse Model, supplied by China Pharmaceuticals Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26 colorectal carcinoma mouse model/product/China Pharmaceuticals Inc
    Average 90 stars, based on 1 article reviews
    ct26 colorectal carcinoma mouse model - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    mouse colorectal carcinoma cells ct26  (ATCC)
    99
    ATCC mouse colorectal carcinoma cells ct26
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Mouse Colorectal Carcinoma Cells Ct26, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse colorectal carcinoma cells ct26/product/ATCC
    Average 99 stars, based on 1 article reviews
    mouse colorectal carcinoma cells ct26 - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    mouse ct26 cl25 colorectal carcinoma cell line  (ATCC)
    95
    ATCC mouse ct26 cl25 colorectal carcinoma cell line
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Mouse Ct26 Cl25 Colorectal Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse ct26 cl25 colorectal carcinoma cell line/product/ATCC
    Average 95 stars, based on 1 article reviews
    mouse ct26 cl25 colorectal carcinoma cell line - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with CT26 on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

    Journal: iScience

    Article Title: Fluorescence tracking Treg movement identifies anti-CCR8 and radiation as a therapeutic combination

    doi: 10.1016/j.isci.2025.114572

    Figure Lengend Snippet: Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with CT26 on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

    Article Snippet: CT26 mouse colorectal carcinoma , ATCC , Cat #: CRL-2638.

    Techniques: Irradiation, Injection